1. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents
    Suliman Almahmoud et al, 2021, Bioorganic & Medicinal Chemistry CrossRef
  2. The Release of Adipose Stromal Cells from Subcutaneous Adipose Tissue Regulates Ectopic Intramuscular Adipocyte Deposition
    Amandine Girousse et al, 2019, Cell Reports CrossRef
  3. The Influence of Anti-Diabetic Drugs on Prostate Cancer
    Miłosz Knura et al, 2021, Cancers CrossRef
  4. Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression
    Giulia Cantini et al, 2021, Journal of Personalized Medicine CrossRef
  5. New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers
    Yi-Fan Dang et al, 2018, Chemico-Biological Interactions CrossRef
  6. The Emerging Role of COX-2, 15-LOX and PPARγ in Metabolic Diseases and Cancer: An Introduction to Novel Multi-target Directed Ligands (MTDLs)
    Rana A. Alaaeddine et al, 2021, Current Medicinal Chemistry CrossRef
  7. Research Progress of PPARγ in Prostate Cancer
    耀 常, 2023, Advances in Clinical Medicine CrossRef
  8. The Effects of Rosiglitazone on the Neonatal Rat Cardiomyocyte Transcriptome: A Temporal Analysis
    Willian Abraham da Silveira et al, 2019, Pharmacogenomics CrossRef
  9. Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies
    Kyung Won Hwang et al, 2023, International Journal of Molecular Sciences CrossRef
  10. HIC1 (Hypermethylated in Cancer 1) modulates the contractile activity of prostate stromal fibroblasts and directly regulates CXCL12 expression
    Marion Dubuissez et al, 2020, Oncotarget CrossRef
  11. Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPARγ
    Suliman Almahmoud et al, 2022, Biomolecules CrossRef
  12. WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer
    Damien A Leach et al, 2016, Endocrine-Related Cancer CrossRef
  13. RETRACTED: Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma
    Paola Maroni et al, 2015, Experimental Cell Research CrossRef
  14. Chaperone-mediated Autophagy Governs Progression of Papillary Thyroid Carcinoma via PPARγ-SDF1/CXCR4 Signaling
    Hong Zhou et al, 2020, The Journal of Clinical Endocrinology & Metabolism CrossRef
  15. Revisiting prostate cancer metabolism: From metabolites to disease and therapy
    Henrique J. Cardoso et al, 2021, Medicinal Research Reviews CrossRef
  16. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway
    Kai Wu et al, 2016, Oncotarget CrossRef
  17. Troglitazone inhibits the migration and invasion of PC‑3 human prostate cancer cells by upregulating E‑cadherin and glutathione peroxidase 3
    Seo‑Na Chang et al, 2018, Oncology Letters CrossRef
  18. The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer
    Cheng Peng et al, 2015, Tumor Biology CrossRef
  19. Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies
    Bahman Yousefi et al, 2016, Chemical Biology & Drug Design CrossRef

  20. Free Fatty Acids Promote the Development of Prostate Cancer by Upregulating Peroxisome Proliferator-Activated Receptor Gamma


    Xiaodan Ha et al, 2020, Cancer Management and Research CrossRef
  21. Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue
    Ibrahim AlZaim et al, 2022, Cancers CrossRef
  22. The impact of thiazolidinediones on the risk for prostate cancer in patients with type 2 diabetes mellitus: A review and meta-analysis
    Moumita Nath et al, 2021, Meta Gene CrossRef
  23. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone
    Mario Nava-Villalba et al, 2015, Molecular Cancer CrossRef
  24. Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression
    Daniela Rovito et al, 2016, Oncotarget CrossRef
  25. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
    Chin-Hsiao Tseng, 2023, Frontiers in Endocrinology CrossRef
  26. Anti-leukemic effects of PPARγ ligands
    Somi Ryu et al, 2018, Cancer Letters CrossRef

  27. The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells


    Zhenyu Wang et al, 2020, Drug Design, Development and Therapy CrossRef
  28. The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy
    Jiaao Sun et al, 2023, Frontiers in Pharmacology CrossRef
  29. Peroxisome proliferator‐activated receptor gamma controls prostate cancer cell growth through AR‐dependent and independent mechanisms
    Catherine C. Elix et al, 2020, The Prostate CrossRef
  30. PPAR-γ Modulators as Current and Potential Cancer Treatments
    Tiange Chi et al, 2021, Frontiers in Oncology CrossRef
  31. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing
    Wenhui Yang et al, 2017, Oncotarget CrossRef